Breast Reduction Free Nipple Incision in Rio de Janeiro Brazil
Breast reduction is an operation that is usually considered a reconstructive procedure and is many times covered by insurance plans. The surgery is performed to make the breasts smaller, as well as lift the breasts to a more youthful position. The purpose of the surgery is to alleviate back and neck pain as well as to aid in hygiene in the folds underneath the breasts.
Marks are made on the skin according to the type of reduction planned by the patient and the surgeon. This is usually performed before the patient is taken back to the operating room with the patient in a sitting or standing position.
The nipple-areola section of skin is removed and saved.
Excess skin and breast tissue is removed.
The incisions are closed with sutures and the nipple-areola skin is reattached.
The patient is placed in a compression garment or bra. Compression garments are an important part of the recovery process. The garment provides support, comfort and helps to minimize swelling. The patient is usually wearing a bra or some type of supportive garment at all times, except when showering. Healing time is approximately three months. Scarring is variable and often depends on the patient's ability to heal.
More Rio de Janeiro info...
Rio de Janeiro By plane
International and most domestic flights land at Gale?o - Ant?nio Carlos Jobim International Airport (better known as Gale?o International Airport) (IATA: GIG) (ICAO: SBGL), Tel: 3398-5050 (fax 3393-2288). This airport is 20 km away from the city center and main hotels. -
Rio de Janeiro Get around The Corcovado mountain (with the Jesus statue on top) can be seen from nearly all of the city.-
Plastic Surgery News...
- Blue Cross and Blue Shield of Massachusetts has proposed paying health care providers a flat fee each year for every patient, rather than paying for each patient visit or treatment, in an attempt to slow health care spending growth, the Boston Globe reports.
- According to research published in the Journal of the American Medical Association, there were no significant differences in clinical outcomes between patients receiving sirolimus- and paclitaxel-eluting stents in everyday clinical practice.
Researchers evaluated sirolimus- and paclitaxel-eluting stents for the prevention of symptom-driven clinical end points, using a study design reflecting everyday clinical practice. The SORT OUT II trial involved 2098 patients treated with percutaneous coronary intervention (PCI) and randomised to receive either sirolimus-eluting (n = 1065) or paclitaxel-eluting (n = 1033) stents. Indications for PCI included ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris, and stable angina. Additionally, dual antiplatelet therapy with aspirin and clopidogrel was recommended for 1 year for all patients. After that period, clopidogrel was discontinued and aspirin continued lifelong, if tolerated.
The primary end point was a composite clinical end point of major adverse cardiac events, defined as either cardiac death, acute myocardial infarction, target lesion revascularisation, or target vessel revascularisation. Secondary end points were individual components of the composite end point, all-cause mortality and stent thrombosis.
The following results were reported:
• With respect to the primary end point, the sirolimus- and the paclitaxel-eluting stent groups did not differ significantly in major adverse cardiac events (98 [9.3%] vs. 114 [11.2%]; hazard ratio, 0.83 [95% confidence interval, 0.63-1.08]; P = 0.16)
• Additionally, no statistically significant differences were reported in stent thrombosis rates, rates of acute myocardial infarction, target lesion or vessel revascularisation, cardiac death or all-cause death
In a related editorial, the authors comment on possible limitations of the study:
1. The study randomised less than a third of the potentially eligible patients, which suggests that the cohort may not be as unselected as the authors had intended for emulating real life practice
2. The study was underpowered due to the small sample size coupled with relatively low event rates